Incyte Corp (INCY) KPIs and segments
Close on Nov 18, 2026Market cap $24.01BP/E 62.7Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Incyte · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Incyte: 31 chỉ số vận hành, trong đó có Jakafi Paid Patient Demand Growth (YoY %), Opzelura Commercial Revenue Growth và Jakavi Ex-U.S. Partnered Royalty Revenue Growth, lấy từ 223 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
JAKAFI($M) | 827 | 817 | 758 | 828 | 791 | 764 | 709 | 773 | 741 | 706 | 572 | 695 | |
OPZELURA($M) | 255 | 450 | 143 | 207 | 188 | 164 | 119 | 162 | 139 | 122 | 85.7 | ||
Product royalty revenues($M) | 191 | 175 | 151 | 184 | 171 | 151 | 131 | 159 | 157 | 137 | 126 | 150 | |
JAKAVI($M) | 132 | 124 | 106 | 130 | 126 | 110 | 92.1 | 114 | 116 | 99.3 | 89.6 | ||
NIKTIMVO($M) | 67.4 | 60.3 | 55.1 | 56.0 | 45.8 | 36.2 | 13.6 | 0 | 0 | 0 | 0 | ||
ZYNYZ($M) | 58.3 | 49.9 | 41.4 | 31.7 | 22.7 | 8.92 | 3.01 | 1.37 | 0.69 | 0.65 | 0.47 | 0.58 | |
MINJUVI/MONJUVI($M) | 54.6 | 53.7 | 49.2 | 41.9 | 42.0 | 31.1 | 29.6 | 32.8 | 31.4 | 31.1 | 23.9 | 8.99 | |
Milestone and contract revenues($M) | 49.8 | 11.2 | 17 | 100 | 45 | 5 | 0 | 0 | 18 | 0 | 25 | 2 | |
OLUMIANT($M) | 39.1 | 38.5 | 36.4 | 37.1 | 33.5 | 30.8 | 34.8 | 31.7 | 30.6 | ||||
OLUMIANT Royalty Revenues($M) | 38.5 | 34.8 | 31.7 | 30.6 | 40.4 | ||||||||
ICLUSIG($M) | 33.5 | 34.4 | 35.5 | 34.2 | 37.6 | 32.7 | 29.5 | 27.4 | 29.7 | 26.9 | 30.3 | 27.1 | |
PEMAZYRE($M) | 21.2 | 23.4 | 22.5 | 22.7 | 22.2 | 18.4 | 23.1 | 20.7 | 20.3 | 17.7 | 20.7 | ||
Other($M) | 12.6 | 5.33 | 3.25 | 3.47 | 1.86 | 1.29 | 1.27 | 0.33 | 0.41 | 0.88 | 0.55 | ||
TABRECTA($M) | 6.83 | 6.69 | 5.98 | 7.14 | 6.51 | 6.63 | 6.41 | 6.29 | 5.93 | 5.30 | 5.23 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)4 | |||||||||||||
United States($M) | 1,435 | 1,560 | 1,171 | 1,425 | 1,261 | 1,132 | 982 | 1,087 | 1,070 | 989 | 828 | ||
Europe($M) | 107 | 105 | 92.4 | 76.0 | 100 | 78.8 | 68.6 | 88.9 | 66.5 | 53.6 | 51.5 | ||
Other countries($M) | 14.9 | 8.80 | 8.78 | 6.08 | 4.41 | 4.35 | 2.73 | 2.51 | 1.37 | 1.14 | 1.20 | ||
Jakafi Paid Patient Demand Growth (YoY %)(%)3 | 12.0% | 9.0% | 6.0% | 11.0% | 10.0% | 8.0% | 10.0% | 14.0% | 10.0% | 9.0% | 5.0% | ||
Jakafi Net Product Revenue Growth — As Reported (YoY %)(%) | 4.0% | 7.0% | 7.0% | 7.0% | 7.0% | 8.0% | 24.0% | 11.0% | 16.0% | 3.0% | -1.0% | 7.0% | |
Jakafi Full-Year Net Product Revenue Guidance — Low Bound($M) | 3,220 | 3,220 | 3,220 | 3,220 | 3,050 | 3,000 | 2,950 | 2,925 | 2,740 | 2,710 | |||
Jakafi Full-Year Net Product Revenue Guidance — High Bound($M) | 3,270 | 3,270 | 3,270 | 3,270 | 3,075 | 3,050 | 3,000 | 2,975 | 2,770 | 2,750 | |||
Opzelura Commercial Revenue Growth — As Reported (YoY %)(%)3 | 36.0% | 173.0% | 20.0% | 28.0% | 35.0% | 35.0% | 38.0% | 48.0% | 52.0% | 52.0% | 52.0% | 78.0% | |
Opzelura International (Ex-U.S.) Net Product Sales($M) | 46.9 | 42.9 | 36.7 | 29.8 | 44.4 | 32.3 | 23.5 | ||||||
Opzelura Full-Year Net Product Revenue Guidance — Low Bound($M) | 1,100 | 1,050 | 750 | 750 | 630 | 630 | 630 | 630 | |||||
Opzelura Full-Year Net Product Revenue Guidance — High Bound($M) | 1,120 | 1,100 | 790 | 790 | 670 | 670 | 670 | 670 | |||||
Jakavi Ex-U.S. Partnered Royalty Revenue Growth — Constant Currency (CER YoY %)(%)16 | 6.0% | 12.0% | 5.0% | 8.0% | 4.0% | 7.0% | 6.0% | 13.0% | 20.0% | 14.0% | 19.0% | 14.0% | |
Jakavi Ex-U.S. Royalty Revenue Growth — As Reported (YoY %)(%) | 5.0% | 13.0% | 15.0% | 14.0% | 9.0% | 10.0% | 3.0% | 10.0% | 20.0% | 10.0% | 17.0% | 14.0% | |
Olumiant Global Royalty Revenue Growth — Constant Currency (CER YoY %)(%) | 8.0% | 16.0% | 12.0% | 2.0% | 4.0% | 4.0% | 6.0% | -3.0% | 22.0% | 4.0% | -8.0% | 12.0% | |
Olumiant Global Royalty Revenue Growth — As Reported (YoY %)(%) | 5.0% | 15.0% | 18.0% | 12.0% | 7.0% | 6.0% | 1.0% | -5.0% | 17.0% | -1.0% | -10.0% | 13.0% | |
Tabrecta Global Royalty Revenue Growth — As Reported (YoY %)(%) | 5.0% | 1.0% | -7.0% | 14.0% | 10.0% | 25.0% | 23.0% | 34.0% | 43.0% | 10.0% | 25.0% | 11.0% | |
Total Royalty Revenues Growth — As Reported (YoY %)(%) | 12.0% | 16.0% | 16.0% | 16.0% | 9.0% | 10.0% | 4.0% | 6.0% | 20.0% | 8.0% | 9.0% | 13.0% | |
Minjuvi / Monjuvi Net Product Revenue Growth — Constant Currency (CER YoY %)(%) | 32.0% | 72.0% | 62.0% | 262.0% | 79.0% | ||||||||
Minjuvi / Monjuvi Net Product Revenue Growth — As Reported (YoY %)(%) | 30.0% | 72.0% | 67.0% | 264.0% | 87.0% | ||||||||
Niktimvo U.S. Net Product Revenue Growth — As Reported (YoY %)(%) | 47.0% | 67.0% | 305.0% | ||||||||||
Iclusig European Net Product Revenue Growth — Constant Currency (CER YoY %)(%) | -10.0% | 3.0% | 8.0% | 15.0% | 19.0% | 16.0% | 1.0% | 6.0% | -7.0% | 8.0% | -6.0% | ||
Iclusig European Net Product Revenue Growth — As Reported (YoY %)(%) | -11.0% | 5.0% | 20.0% | 25.0% | 26.0% | 22.0% | -3.0% | 1.0% | 7.0% | -8.0% | 10.0% | -2.0% | |
Pemazyre Net Product Revenue Growth — Constant Currency (CER YoY %)(%) | -6.0% | 5.0% | 19.0% | -1.0% | 9.0% | 8.0% | 6.0% | 12.0% | 9.0% | -6.0% | -22.0% | -11.0% | |
Pemazyre Net Product Revenue Growth — As Reported (YoY %)(%) | -7.0% | 6.0% | 22.0% | 1.0% | 10.0% | 9.0% | 4.0% | 12.0% | -21.0% | 151.0% | 33.0% | -10.0% | |
Zynyz Net Product Revenue Growth — Constant Currency (CER YoY %)(%) | 158.0% | 458.0% | 1,269.0% | 136.0% | 608.0% | ||||||||
Zynyz Net Product Revenue Growth — As Reported (YoY %)(%) | 157.0% | 460.0% | 1,276.0% | 3,167.0% | 1,270.0% | 544.0% | 136.0% | 608.0% | 14.0% | ||||
Total Net Product Revenues Growth — As Reported (YoY %)(%) | 14.0% | 40.0% | 20.0% | 20.0% | 19.0% | 17.0% | 26.0% | 18.0% | 23.0% | 10.0% | 5.0% | 13.0% | |
Total Consolidated GAAP Revenues Growth — As Reported (YoY %)(%) | 14.0% | 38.0% | 21.0% | 28.0% | 20.0% | 16.0% | 20.0% | 16.0% | 24.0% | 9.0% | 9.0% | 9.0% | |
Hematology & Oncology Portfolio Net Product Sales (ex-Jakafi, ex-Opzelura)($M)9 | 235 | 222 | 204 | ||||||||||
Hematology & Oncology Portfolio Revenue Growth (YoY %)(%) | 38.0% | 69.0% | 116.0% | ||||||||||
Hematology & Oncology Portfolio Full-Year Net Sales Guidance — Low Bound($M) | 890 | 860 | 800 | 800 | 550 | 500 | 415 | 415 | |||||
Hematology & Oncology Portfolio Full-Year Net Sales Guidance — High Bound($M) | 910 | 890 | 880 | 880 | 575 | 520 | 455 | 455 | |||||
Total Net Product Revenues Full-Year Guidance — Low Bound($M) | 5,210 | 5,130 | 4,770 | 4,770 | |||||||||
Total Net Product Revenues Full-Year Guidance — High Bound($M) | 5,300 | 5,260 | 4,940 | 4,940 | |||||||||
Combined GAAP R&D and SG&A Expenses Full-Year Guidance — Low Bound($M) | 4,915 | 4,915 | 3,495 | 3,495 | |||||||||
Combined GAAP R&D and SG&A Expenses Full-Year Guidance — High Bound($M) | 4,995 | 4,995 | 3,675 | 3,675 | |||||||||
Combined Non-GAAP R&D and SG&A Expenses Full-Year Guidance — Low Bound($M) | 4,625 | 4,625 | 3,205 | 3,205 | |||||||||
Combined Non-GAAP R&D and SG&A Expenses Full-Year Guidance — High Bound($M) | 4,695 | 4,695 | 3,375 | 3,375 | |||||||||
Specialty Distributor Concentration — Customer B Share of Net Product Revenues(%)6 | 22.0% | 7.0% | 8.0% | 20.0% | 9.0% | 10.0% | 10.0% | 10.0% | 11.0% | ||||
Specialty Distributor Concentration — Customer C Share of Net Product Revenues(%) | 18.0% | 20.0% | 21.0% | 18.0% | 20.0% | 20.0% | 20.0% | 18.0% | 18.0% | ||||
Specialty Distributor Concentration — Customer D Share of Net Product Revenues(%) | 12.0% | 19.0% | 19.0% | 10.0% | 19.0% | 19.0% | 13.0% | 13.0% | 12.0% | ||||
Specialty Distributor Concentration — Customer E Share of Net Product Revenues(%) | 11.0% | 12.0% | 10.0% | 11.0% | 11.0% | 9.0% | 10.0% | 10.0% | 10.0% | ||||
Specialty Distributor Concentration — Customer A Share of Net Product Revenues(%) | 10.0% | 11.0% | 13.0% | 14.0% | 13.0% | 14.0% | 15.0% | 15.0% | 17.0% | ||||
Major Wholesalers Combined Share of Gross Accounts Receivable(%) | 59.0% | 63.0% | 64.0% | 59.0% | 50.0% | 51.0% | 49.0% | 41.0% | 40.0% | ||||
Novartis & Eli Lilly Combined Royalty Share of Accounts Receivable(%) | 14.0% | 15.0% | 14.0% | 17.0% | 20.0% | 18.0% | 16.0% | 19.0% | 21.0% | 18.0% | 20.0% | ||
Total Gross-to-Net (GTN) Sales Allowance Reserves — Ending Balance($M)9 | 631 | 534 | 730 | 646 | 607 | 549 | 475 | 446 | 388 | 357 | 366 | 286 | |
GTN Ending Reserve — Commercial & Government Rebates and Chargebacks($M) | 526 | 445 | 641 | 562 | 529 | 481 | 407 | 383 | 339 | 309 | 323 | 242 | |
GTN Ending Reserve — Prompt-Pay Discounts & Distribution Fees($M) | 46.6 | 42.4 | 38.6 | 38.8 | 39.9 | 29.2 | 29.4 | 27.4 | 20.0 | 21.2 | 18.4 | 20.5 | |
GTN Ending Reserve — Product Returns Allowance($M) | 37.6 | 32.1 | 32.8 | 31.0 | 28.8 | 26.5 | 25.8 | 23.0 | 17.7 | 15.6 | 11.7 | 11.0 | |
GTN Ending Reserve — Patient Co-Pay Assistance & Other Deductions($M) | 21.0 | 13.8 | 18.1 | 14.2 | 9.64 | 12.6 | 12.5 | 13.3 | 10.8 | 10.6 | 13.3 | 13.0 | |
Accrued Sales Allowances — Current Liability Portion (Balance Sheet)($M) | 624 | 526 | 722 | 642 | 600 | 542 | 468 | 438 | 382 | 350 | 359 | 280 | |
GTN Provisions Recorded for Current-Year Product Sales($M)4 | 756 | 598 | 691 | 612 | 514 | 511 | 454 | 449 | 391 | 378 | 372 | 344 | |
GTN Provisions (Credits) Recorded for Prior-Year Product Sales($M)3 | -1.20 | -168 | -58.0 | -0.43 | -2.67 | -3.65 | -8.64 | 4.59 | -0.76 | 4.14 | -0.51 | 0.44 | |
GTN Credits & Payments Settled for Current-Year Product Sales($M)3 | 630 | 494 | 411 | 522 | 447 | 412 | 270 | 371 | 354 | 363 | 218 | 286 | |
GTN Credits & Payments Settled for Prior-Year Product Sales($M)4 | 26.9 | 132 | 138 | 51.2 | 6.60 | 20.7 | 147 | 24.2 | 5.05 | 28.4 | 95.5 | 9.90 | |
Total Commercial & Biologics Inventory (Current + Noncurrent)($M)6 | 476 | 458 | 447 | 443 | 450 | 452 | 429 | 407 | 368 | 356 | 328 | 270 | |
Work-in-Process Drug Substance & Biologics Inventory($M) | 356 | 338 | 352 | 344 | 354 | 362 | 352 | 331 | 286 | 285 | 255 | 210 | |
Finished Goods Commercial Inventory($M) | 71.4 | 70.0 | 58.9 | 71.8 | 64.9 | 56.8 | 47.5 | 48.4 | 47.4 | 46.7 | 49.5 | 36.9 | |
Raw Materials Inventory($M) | 48.9 | 49.8 | 36.6 | 27.9 | 30.7 | 33.0 | 29.9 | 27.6 | 35.5 | 24.6 | 23.4 | 23.3 | |
Current Inventory, Net (Balance Sheet)($M) | 134 | 113 | 116 | 101 | 83.4 | 83.4 | 64 | 58.9 | 70.4 | 101 | 63.6 | 63 | |
Noncurrent Multi-Year Biologics & API Inventory (Other Long-Term Assets)($M) | 342 | 345 | 331 | 342 | 367 | 368 | 365 | 348 | 298 | 255 | 264 | 207 | |
Pre-Approval Manufacturing Inventory Expensed to R&D (Prior to Regulatory Approval)($M) | 32.3 | 39.1 | 40.9 | 43.6 | 45.4 | 47.4 | 27.7 | 28.3 | 32.3 | 34.9 | 38.2 | 35.6 | |
External Clinical CRO & Contract R&D Expense (ASU 2023-07 Segment Disaggregation)($M)7 | 271 | 248 | 243 | 272 | 256 | 246 | 193 | 213 | 223 | 224 | 205 | ||
Internal R&D Personnel, Lab & Facility Expense (ASU 2023-07)($M) | 284 | 269 | 260 | 270 | 250 | 237 | 228 | 250 | 250 | 235 | 223 | ||
Upfront Acquired IPR&D, License & Milestone R&D Expense (ASU 2023-07)($M) | 1,237 | 0 | 12.6 | 69.4 | 0.10 | 12.6 | 15.5 | 3.00 | 100 | 680 | 1 | ||
R&D — Clinical Research & Outside Services (MD&A Natural Breakdown)($M) | 317 | 292 | 294 | 390 | 279 | 286 | 229 | 249 | 352 | 248 | 227 | 260 | |
R&D — Salaries, Benefits & Headcount Costs (MD&A)($M) | 168 | 146 | 154 | 147 | 147 | 132 | 133 | 131 | 132 | 121 | 123 | 103 | |
R&D — Share-Based Compensation (MD&A)($M) | 43.5 | 38.2 | 39.2 | 36.1 | 39.7 | 37.7 | 36.7 | 44.2 | 45.8 | 34.5 | 36.8 | 36 | |
R&D — Facility Occupancy, Lab Supplies & Other (MD&A)($M) | 31.8 | 40.4 | 28.6 | 38.3 | 41.1 | 39.3 | 38.7 | 42 | 44.1 | 45 | 43.2 | 45.3 | |
Collaborative Partner R&D Cost Reimbursements (Contra-R&D Credit)($M) | 4 | 4.40 | 4.40 | 5.20 | 4.30 | 3.90 | 4.20 | 17.1 | 12.1 | ||||
Accrued Clinical Trial & CRO Liabilities (Ending Balance)($M)17 | 163 | 164 | 178 | 176 | 158 | 146 | 133 | 132 | 121 | 106 | 94.6 | 110 | |
U.S. Jakafi Royalties Expensed to Novartis (Cost of Product Revenues)($M) | 20.2 | 20 | 16.1 | 20.3 | 19.3 | 18.7 | 29.8 | 37.9 | 36.3 | 34.6 | 23 | 34.1 | |
Accrued U.S. Jakafi Royalty Payable to Novartis($M) | 20.2 | 20 | 16.1 | 20.3 | 19.4 | 18.7 | 537 | 507 | 470 | 433 | 399 | 376 | |
Syndax U.S. Niktimvo 50% Profit-Share Expense (Cost of Product Revenues)($M) | 20.3 | 20.2 | 14.4 | 19.4 | 14.3 | ||||||||
Syndax Axatilimab Co-Development R&D Expense Recognized by Incyte($M) | 4.80 | 4.90 | 5.40 | 5.60 | 6.30 | 5.30 | 4.70 | 1.20 | 5.80 | 4.70 | 7.10 | 8.90 | |
Accrued Commercialization Payable to Syndax (U.S. Niktimvo)($M) | 29.5 | 26.5 | 22.5 | 27.6 | |||||||||
Accrued Co-Development Payable to Syndax($M) | 1.40 | 1.40 | 1.40 | 2.40 | 2.20 | ||||||||
Total Accrued Third-Party Royalties — Current Liability($M) | 45.0 | 42.8 | 37.5 | 40.7 | 36.9 | 33.1 | 549 | 520 | 491 | 444 | 410 | 387 | |
Accrued Commercial Sales & Marketing Liabilities($M) | 58.9 | 60.3 | 64.8 | 71.2 | 48.9 | 51.3 | 53.8 | 33.4 | 40.6 | 39.5 | 42.0 | 37.4 | |
Acquisition-Related Contingent Consideration Liability (Level 3 Fair Value)($M) | 92 | 102 | 110 | 121 | 184 | 207 | 195 | 193 | 207 | 194 | 202 | 212 | |
Contingent Consideration Financing Cash Payments($M) | 4.60 | 4.60 | 4.96 | 4.96 | 4.96 | 4.96 | 5.37 | ||||||
Cumulative Novartis Regulatory Milestones Achieved (Jakavi & Tabrecta)($M) | 345 | 345 | 345 | 345 | 345 | 345 | 345 | 345 | 345 | 345 | 345 | 345 | |
Cumulative Novartis Commercial Sales Milestones Achieved($M) | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | |
Cumulative Novartis Development Milestones Achieved($M) | 157 | 157 | 157 | 157 | 157 | 157 | 157 | 157 | 157 | 157 | 157 | 157 | |
Cumulative Eli Lilly Regulatory Milestones Achieved (Olumiant)($M) | 335 | 335 | 335 | 335 | 335 | 335 | 335 | 335 | 335 | 335 | 335 | 335 | |
Cumulative Eli Lilly Development Milestones Achieved (Olumiant)($M) | 149 | 149 | 149 | 149 | 149 | 149 | 149 | 149 | 149 | 149 | 149 | 149 | |
Cumulative Eli Lilly Commercial Sales Milestones Achieved (Olumiant)($M) | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | |
Cumulative MacroGenics Milestones Paid (Retifanlimab / Zynyz)($M) | 215 | 215 | 215 | 215 | 215 | 215 | 215 | 215 | 215 | 115 | 115 | 115 | |
Commercial Selling & Marketing Expense (ASU 2023-07 Segment Disaggregation)($M)12 | 297 | 286 | 260 | 308 | 272 | 256 | 258 | 258 | 242 | 229 | 217 | ||
General & Administrative Expense (ASU 2023-07 Segment Disaggregation)($M) | 67.4 | 66.0 | 68.5 | 81.9 | 56.8 | 74.7 | 68.0 | 69.2 | 67.3 | 76.8 | 83.4 | ||
Change in Fair Value of Contingent Consideration (Segment Disaggregation)($M) | 0.89 | 2.50 | -0.17 | -28.3 | -12.2 | 22.8 | 11.6 | -4.04 | 23.4 | 0.89 | -0.46 | ||
Other Segment Expense & Non-Operating Items (ASU 2023-07)($M) | 76.4 | 112 | -2.21 | 36.6 | 19.3 | 125 | 47.0 | 100 | 39.6 | -33.5 | -77.7 | ||
Cost of Product Revenues — Partner Royalty Expense (MD&A)($M) | 40.8 | 38.3 | 32.1 | 34.2 | 30.8 | 25.9 | 33.7 | 40.5 | 38.5 | 36.9 | 25.1 | 35.4 | |
Cost of Product Revenues — Drug Manufacturing & Product Costs (MD&A)($M) | 32.7 | 28.4 | 41 | 50.1 | 41.1 | 30.7 | 27.4 | 32.2 | 38.2 | 31.2 | 27.4 | 25.4 | |
Cost of Product Revenues — Collaboration Profit-Share Expense (MD&A)($M) | 20.3 | 20.2 | 14.4 | 19.4 | 14.3 | 10.3 | |||||||
Cost of Product Revenues — Acquired Product Rights Amortization (MD&A)($M) | 7 | 7 | 6.90 | 6.70 | 6.90 | 6 | 6 | 6.10 | 6.10 | 5.70 | 5.70 | 5.80 | |
Cost of Product Revenues — Manufacturing Salaries & Benefits (MD&A)($M) | 6.70 | 10.2 | 9.20 | 9.80 | 5 | 5.10 | 5.20 | 9 | 2.60 | 2.40 | 2.20 | 2.50 | |
Cost of Product Revenues — Share-Based Compensation (MD&A)($M) | 1.20 | 0.90 | 0.90 | 0.90 | 0.90 | 0.80 | 0.90 | 0.70 | 0.60 | 0.40 | 0.60 | 0.70 | |
SG&A — Commercial Marketing & Outside Contract Services (MD&A)($M) | 217 | 216 | 195 | 243 | 203 | 211 | 205 | 209 | 186 | 181 | 195 | 192 | |
SG&A — Commercial & Corporate Salaries and Benefits (MD&A)($M) | 123 | 108 | 109 | 122 | 105 | 94.2 | 97.8 | 91.3 | 91.7 | 83.4 | 83.2 | 78.6 | |
SG&A — Share-Based Compensation (MD&A)($M) | 25.1 | 28.2 | 24 | 25.1 | 21 | 26.1 | 23.4 | 26.9 | 31.5 | 21.7 | 22.4 | 23.3 | |
Non-GAAP Adjusted Diluted Net Income (Loss) Per Share($)6 | -3.60 | 3.09 | 1.81 | 1.80 | 2.26 | 1.57 | 1.16 | 1.43 | 1.07 | -1.82 | 0.64 | 1.06 | |
Non-GAAP Adjusted Basic Net Income (Loss) Per Share($) | -3.60 | 3.21 | 1.88 | 1.86 | 2.33 | 1.61 | 1.18 | 1.46 | 1.09 | -1.82 | 0.65 | 1.07 | |
Non-GAAP Adjusted Operating Income (Loss)($M) | -630 | 773 | 394 | 451 | 498 | 383 | 284 | 376 | 255 | 161 | 268 | ||
Non-GAAP Adjusted Net Income (Loss)($M) | -731 | 643 | 374 | 368 | 456 | 312 | 229 | 281 | 210 | 145 | 239 | ||
Non-GAAP Adjusted Cost of Product Revenues($M) | 102 | 98.6 | 98.3 | 115 | 92.7 | 72.5 | 66.9 | 82.4 | 80.0 | 70.9 | 55.0 | 63.6 | |
Non-GAAP Adjusted Research & Development Expense($M) | 1,746 | 479 | 477 | 575 | 467 | 456 | 400 | 420 | 525 | 1,089 | 388 | 408 | |
Non-GAAP Adjusted Selling, General & Administrative Expense($M) | 339 | 324 | 304 | 365 | 308 | 305 | 302 | 300 | 277 | 263 | 277 | 271 | |
Cash Capital Expenditures (Bridged Productive Asset Additions)($M)2 | 15.6 | 12.4 | 10.2 | 21.9 | 14.7 | 19.1 | 3.17 | 17.4 | 5.19 | 54.1 | 9.55 | 2.27 | |
Capital Expenditures Incurred Included in Accounts Payable & Accruals($M) | 0.65 | 0.00 | 1.63 | 4.93 | 4.16 | 4.05 | 2.89 | 2.60 | 3.54 | 0.80 | 0.38 | 5.05 | |
Cash Payments to Acquire Commercial Product Rights & Intangible Assets($M) | 0 | 0 | 5 | 0 | 25 | 0 | 0 | 0 | 12.5 | 1.40 | 0 | 0 | |
Property, Plant & Equipment, Gross (Total)($M)8 | 1,116 | 1,113 | 1,109 | 1,106 | 1,159 | 1,145 | 1,109 | 1,091 | 1,089 | 1,060 | 1,003 | 1,021 | |
PP&E Gross — Buildings & Leasehold Improvements (Wilmington Campus & Yverdon Biologics Plant)($M) | 598 | 607 | 609 | 610 | 628 | 627 | 602 | 597 | 585 | 573 | 572 | 585 | |
PP&E Gross — Laboratory & Biologics Manufacturing Equipment($M) | 261 | 261 | 260 | 258 | 252 | 250 | 235 | 230 | 232 | 222 | 217 | 221 | |
PP&E Gross — Computer Hardware & Software Systems($M) | 171 | 168 | 161 | 152 | 149 | 147 | 160 | 157 | 154 | 152 | 150 | 148 | |
PP&E Gross — Construction in Progress($M) | 33.8 | 26.7 | 25.1 | 30.5 | 69.7 | 57.4 | 50.2 | 46.1 | 60.0 | 55.8 | 10.8 | 13.5 | |
PP&E Gross — Office Furniture & Equipment($M) | 24.8 | 25.5 | 25.3 | 24.4 | 24.4 | 24.4 | 23.8 | 23.7 | 23.8 | 23.5 | 23.4 | 23.4 | |
PP&E Gross — Operating Lease Right-of-Use Assets($M) | 15.3 | 14.4 | 18.3 | 19.6 | 20.1 | 21.9 | 22.3 | 22.2 | 17.3 | 18.1 | 18.0 | 20.6 | |
PP&E Gross — Land (Wilmington Headquarters Campus)($M) | 11.0 | 11.2 | 11.2 | 11.3 | 16.1 | 16.1 | 15.5 | 15.4 | 15.8 | 15.4 | 10.6 | 10.9 | |
Less: Accumulated Depreciation & Amortization($M) | 415 | 404 | 389 | 375 | 361 | 346 | 344 | 328 | 316 | 298 | 283 | 270 | |
Total Operating & Finance Lease Liabilities5 | |||||||||||||
Finance Lease Right-of-Use Assets, Net($M) | 24.7 | 25.6 | 26.7 | 27.5 | 28.2 | 29.0 | 29.9 | 30.8 | 25.1 | 25.5 | 25.5 | 25.5 | |
Finance Lease Liabilities — Noncurrent($M) | 27.6 | 28.4 | 29.4 | 30.2 | 30.9 | 31.8 | 32.6 | 33.5 | 28.2 | 28.7 | 28.9 | 29.2 | |
Finance Lease Liabilities — Current($M) | 4.13 | 4.26 | 4.41 | 4.52 | 4.49 | 4.48 | 4.48 | 4.42 | 3.93 | 3.87 | 3.68 | 3.44 | |
Operating Lease Liabilities — Current($M) | 5.65 | 5.59 | 5.60 | 5.70 | 5.90 | 6.17 | 6.00 | 5.58 | 4.35 | 4.93 | 4.78 | 5.69 | |
Finance Lease Principal Cash Payments($M) | 1.15 | 1.16 | 1.18 | 1.11 | 1.14 | 1.16 | 1.09 | 1.04 | 0.98 | 0.91 | 0.87 | 0.88 | |
Marketable Debt Securities — Total Fair Value($M)6 | 579 | 553 | 555 | 483 | 475 | 467 | 467 | 470 | 467 | 462 | 504 | 443 | |
Marketable Debt Securities — Amortized Cost Basis($M) | 586 | 556 | 555 | 481 | 473 | 465 | 466 | 470 | 464 | 464 | 506 | 443 | |
Available-for-Sale Debt Securities Maturing Within 1 Year($M) | 212 | 206 | 217 | 189 | 178 | 221 | 257 | 265 | |||||
Available-for-Sale Debt Securities Maturing in 1 to 5 Years($M) | 367 | 348 | 338 | 293 | 297 | 245 | 210 | 205 | |||||
Purchases of Marketable Debt Securities($M) | 72.7 | 31.4 | 143 | 82.7 | 116 | 56.1 | 41.2 | 29.4 | 24.9 | 38.3 | 166 | 234 | |
Proceeds from Maturities of Marketable Debt Securities($M) | 44 | 32 | 69.7 | 75.0 | 108 | 56.3 | 45.5 | 23.4 | 25.2 | 80.4 | 102 | 81.6 | |
Noncurrent Restricted Cash($M) | 1.76 | 1.82 | 1.84 | 1.85 | 1.84 | 1.84 | 1.67 | 1.62 | 1.74 | 1.63 | 1.63 | 1.84 | |
Total Share-Based Compensation Expense($M)16 | 69.8 | 67.3 | 64.1 | 62.1 | 61.6 | 64.6 | 61 | 71.8 | 77.9 | 56.6 | 59.8 | 60 | |
Share-Based Compensation — Research & Development($M) | 43.5 | 38.2 | 39.2 | 36.1 | 39.7 | 37.7 | 36.7 | 44.2 | 45.8 | 34.5 | 36.8 | 36 | |
Share-Based Compensation — Selling, General & Administrative($M) | 25.1 | 28.2 | 24 | 25.1 | 21 | 26.1 | 23.4 | 26.9 | 31.5 | 21.7 | 22.4 | 23.3 | |
Share-Based Compensation — Cost of Product Revenues($M) | 1.20 | 0.90 | 0.90 | 0.90 | 0.90 | 0.80 | 0.90 | 0.70 | 0.60 | 0.40 | 0.60 | 0.70 | |
Share-Based Compensation — Performance Shares (PSUs)($M) | 6.40 | 8.40 | 7 | 7.10 | 2.60 | 6.90 | 3.10 | 10.9 | 12.3 | 3.50 | 3.40 | 3.80 | |
Cash Proceeds from Employee Stock Option Exercises & ESPP($M) | 122 | 75.1 | 97.9 | 160 | 43.4 | 14.9 | 3.24 | 33.1 | 1.28 | 14.5 | 0.48 | 7.52 | |
Cash Paid for Employee Tax Withholdings on Net Share Settlements($M) | 103 | 3.93 | 6.96 | 16.3 | 50.1 | 0.91 | 9.45 | 0.89 | 32.6 | 0.69 | 6.17 | 0.49 | |
Stock Options Outstanding (Ending Shares, Millions)(M) | 8.39 | 8.98 | 9.71 | 10.9 | 12.9 | 13.0 | 13.1 | 12.8 | 13.2 | 12.9 | 12.9 | 12.5 | |
Stock Options Outstanding — Weighted-Average Exercise Price($) | 87.70 | 85.36 | 85.07 | 83.46 | 82.83 | 82.71 | 83.13 | 83.45 | 83.16 | 84.15 | 84.29 | 85.40 | |
Stock Options Granted (Shares, Millions)(M) | 0.85 | 0.10 | 0.33 | 0.09 | 0.59 | 0.21 | 0.53 | 0.02 | 0.60 | 0.13 | 0.60 | 0.12 | |
Stock Options Granted — Weighted-Average Black-Scholes Fair Value($) | 40.64 | 36.50 | 33.34 | 23.58 | 25.04 | 22.67 | 21.54 | 20.18 | 20.67 | ||||
Stock Options Exercised (Shares, Millions)(M) | 1.35 | 0.74 | 1.32 | 1.92 | 0.60 | 0.02 | 0.05 | 0.37 | 0.02 | 0.03 | 0.01 | 0 | |
Restricted Stock Units (RSUs) Granted (Shares, Millions)(M) | 2.04 | 0.09 | 0.28 | 0.07 | 2.91 | 0.17 | 0.35 | 0.09 | 2.98 | 0.08 | 0.33 | 0.07 | |
Restricted Stock Units (RSUs) Vested & Released (Shares, Millions)(M) | 2.29 | 0.11 | 0.24 | 0.36 | 1.99 | 0.06 | 0.45 | 0.04 | 1.47 | 0.05 | 0.34 | 0.03 | |
Performance Stock Units (PSUs) Vested & Released (Shares, Millions)(M) | 0.28 | 0 | 0.02 | 0.11 | 0 | 0 | |||||||
Shares Available for Future Equity Grant Under Stock Incentive Plan (Millions)(M) | 5.80 | 8.72 | 8.79 | 9.06 | 8.87 | 11.8 | 3.16 | 4.01 | 4 | 10.7 | 10.8 | 10.8 | |
Anti-Dilutive Potential Common Shares Excluded from Diluted EPS (Millions)(M) | 9.24 | 2.34 | 2.50 | 8.11 | 12.4 | 11.1 | 13.1 | 16.1 | 13.2 | ||||
Cash Income Taxes Paid, Net of Refunds($M) | 11.9 | 15.2 | -8.79 | 27.0 | 7.30 | 177 | 0.84 | 70.2 | 73.2 | 227 | 2.69 | 125 | |
Novartis AG (NVS) — Jakavi Ex-U.S. End-Market Commercial Net Sales($M)2 | 564 | 576 | 557 | 555 | 539 | 524 | 492 | 487 | 500 | 471 | 478 | 444 | |
Novartis AG (NVS) — Jakavi Commercial Sales Constant-Currency Growth (CER YoY %)(%) | 5.0% | 8.0% | 5.0% | 8.0% | 4.0% | 8.0% | 7.0% | 13.0% | 18.0% | 13.0% | 18.0% | 14.0% | |
Novartis AG (NVS) — Jakavi Commercial Sales USD Growth (YoY %)(%) | 5.0% | 10.0% | 13.0% | 14.0% | 8.0% | 11.0% | 3.0% | 10.0% | 17.0% | 8.0% | 15.0% | 14.0% | |
Syndax Pharmaceuticals, Inc. (SNDX) — U.S. Niktimvo Quarterly Infusions Administered2 | 6,350 | 5,750 | 5,000 | 5,000 | 4,500 | ||||||||
Syndax Pharmaceuticals, Inc. (SNDX) — 50% Share of U.S. Niktimvo Net Commercial Profit($M) | 22.6 | 18.1 | 15.9 | 28.5 | 13.9 | 9.36 | -0.25 | ||||||
Syndax Pharmaceuticals, Inc. (SNDX) — Direct External Axatilimab Clinical R&D Expense($M) | 7.47 | 8.68 | 9.63 | 9.45 | 9.05 | 19.7 | 24.2 | 8.50 | 5.60 | ||||
U.S. Real Personal Consumption Expenditures — Health Care Services (FRED: DHLCRC1Q027SBEA, Chained $M SAAR)($M) | 3,858,671 | 3,790,292 | 3,699,899 | 3,666,986 | 3,614,854 | 3,529,833 | 3,464,650 | 3,417,834 | 3,358,244 | 3,288,215 | 3,244,355 | 3,159,378 | |
Total Consolidated GAAP Revenues($M)7 | 1,557 | 1,674 | 1,273 | 1,507 | 1,366 | 1,216 | 1,053 | 1,179 | 1,138 | 1,044 | 881 | 1,013 | |
Cost of Product Revenues (GAAP)($M) | 109 | 105 | 105 | 121 | 99 | 78.8 | 73.2 | 88.5 | 86 | 76.6 | 61 | 69.8 | |
Research & Development Expense (GAAP)($M) | 1,792 | 517 | 516 | 611 | 507 | 495 | 437 | 466 | 573 | 1,138 | 429 | 445 | |
Selling, General & Administrative Expense (GAAP)($M) | 364 | 352 | 328 | 390 | 329 | 331 | 326 | 327 | 309 | 306 | 300 | 288 | |
Operating Income (Loss) (GAAP)($M) | -708 | 698 | 301 | 336 | 444 | 530 | 205 | 302 | 146 | -478 | 91.9 | 187 | |
Net Income (Loss) Attributable to Common Stockholders (GAAP)($M) | -785 | 586 | 303 | 299 | 424 | 405 | 158 | 201 | 107 | -445 | 170 | 201 | |
Diluted Net Income (Loss) Per Share (GAAP)($) | -3.86 | 2.81 | 1.47 | 2.11 | 2.04 | 0.80 | 0.54 | -2.04 | 0.75 | ||||
Weighted-Average Diluted Shares Outstanding (Millions)(M) | 203 | 208 | 207 | 201 | 199 | 198 | 196 | 218 | 227 | ||||
Net Cash Provided by (Used in) Operating Activities (GAAP)($M)3 | -675 | 508 | 369 | 543 | 559 | 44.7 | 266 | 381 | 311 | -576 | 219 | 148 | |
Total Consolidated Assets (GAAP)($M) | 7,287 | 7,873 | 7,339 | 6,958 | 6,330 | 5,821 | 5,749 | 5,444 | 5,012 | 4,662 | 7,136 | 6,782 | |
Total Consolidated Liabilities (GAAP)($M) | 1,644 | 1,528 | 1,716 | 1,791 | 1,679 | 1,651 | 2,082 | 1,997 | 1,841 | 1,665 | 1,741 | 1,592 | |
Total Stockholders' Equity (GAAP)($M) | 5,643 | 6,344 | 5,623 | 5,168 | 4,651 | 4,171 | 3,668 | 3,448 | 3,171 | 2,997 | 5,394 | 5,190 | |
6 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Incyte Corporation (NASDAQ: INCY, CIK 0000879169) operates on a calendar fiscal year ending December 31 (latest completed fiscal year: FY2025 ended December 31, 2025; latest completed fiscal quarter: Q3 2026 / FY2026Q3 ended September 30, 2026). Incyte manages and reports its global biopharmaceutical operations as a single operating and reportable segment.
- Commercial operations span three pillars: (1) flagship JAK1/JAK2 inhibitor Jakafi / Jakafi XR (ruxolitinib) in the United States across polycythemia vera (PV), myelofibrosis (MF), and graft-versus-host disease (GVHD) (+12% YoY paid patient demand growth in Q3 2026; FY2026 guidance raised to $3,220M–$3,270M); (2) topical JAK inhibitor Opzelura (ruxolitinib cream) in atopic dermatitis and nonsegmental vitiligo across the U.S. and international markets ($46.9M ex-U.S. sales and +36% YoY global growth in Q3 2026); and (3) the expanding Hematology & Oncology portfolio ($235.0M in Q3 2026, +38% YoY), led by U.S. 50/50 co-commercialized Niktimvo (axatilimab-csfr; ~6,350 infusions administered in Q3 2026 per partner Syndax), wholly-owned global Monjuvi / Minjuvi (tafasitamab), Iclusig, Pemazyre, and Zynyz, alongside royalties from Novartis (ex-U.S. Jakavi: $564M Q3 2026 partner sales; Tabrecta) and Eli Lilly (Olumiant).
- Key operational disclosures include the 5-column Gross-to-Net (GTN) rebate, chargeback, distribution, return, and co-pay reserve rollforward ($631.5M ending total GTN reserve at September 30, 2026), specialty distributor channel concentration, multi-stage small-molecule & biologics inventory ($475.8M current + noncurrent inventory at Q3 2026), ASU 2023-07 external vs. internal R&D disaggregation, bridged Cash Capital Expenditures across 2018–2026, global workforce & SASB environmental/quality metrics, and standalone UK statutory filings for wholly-owned subsidiary Incyte Biosciences UK Ltd (#08247692; £25.17M turnover and 30 FTEs in FY2025).
- Under U.S. GAAP, Incyte does not publish standalone parent-only financial statements (Form 10-K omits Schedule I as restricted net assets are immaterial), so no Consolidated − Parent-only subtraction is performed. All metrics are strictly as published (with verbatim hover quotes for text-extracted figures; bound-qualified numbers such as 'Over 400,000 patients' are excluded). The only arithmetic shown in table cells is period splitting from cumulative YTD and full-year disclosures (Q2 = 6M − Q1; Q3 = 9M − 6M; Q4 = full year − 9M), displayed in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (12)
- Brand-level dollar revenues (Jakafi, Opzelura, Niktimvo, Minjuvi/Monjuvi, Iclusig, Pemazyre, Zynyz), partnered royalty dollar lines (Jakavi, Olumiant, Tabrecta), and consolidated geographic revenues (U.S., Europe, Other Countries) — Already displayed in the Segments section above; excluded here to avoid duplication while retaining non-overlapping Opzelura Ex-U.S. sales, Hematology & Oncology portfolio totals, patient demand YoY %, and CER growth rates.
- Eli Lilly and Company (LLY) — Olumiant (baricitinib) global end-market commercial sales — Eli Lilly discontinued separate product-line revenue disclosure for Olumiant after Q4 2024, failing the recent 3-quarter continuity requirement.
- SASB HC-BP-000.A Total Patients Treated ('Over 400,000 patients treated' in the 2025 Global Responsibility Report) — Excluded because management discloses only a bound-qualified figure ('Over ...') rather than a point value.
- Syndax Pharmaceuticals (SNDX) — U.S. Niktimvo Q1 2025 ('More than 1,250') & Q2 2025 ('>4,000') infusions and quarterly new patient starts ('>300 new patients' in Q4 2025, Q2 2026, Q3 2026) — Bound-qualified disclosures ('>' / 'More than') are excluded; exact point-estimate quarterly infusions (~4,500 to ~6,350 across Q3 2025–Q3 2026) are included.
- Constant-Currency (CER YoY %) revenue growth for U.S.-only Jakafi & Niktimvo (0.00 percentage point FX variance) and Opzelura & Total Net Product Sales (<1.0 percentage point average FX variance) — Excluded because CER growth adds no incremental FX signal over reported USD YoY % on U.S.-predominant lines.
- Standalone Full-Year GAAP & Non-GAAP R&D and SG&A Guidance Lines (2019–Q3 2025) — Beginning with initial FY2026 guidance in Q4 2025, Incyte transitioned from separate R&D and SG&A guidance ranges to combined GAAP and Non-GAAP R&D + SG&A guidance.
- Quarterly Jakafi & Opzelura MD&A Volume vs. Price Dollar Variance (missing Q1 2026 dollar disaggregation) — Excluded due to a gap in Q1 2026 Form 10-Q MD&A narrative.
- Quarterly Earnings Call Slide Decks on investor.incyte.com (Akamai CDN HTTP 403 block on automated requests) — Operational call metrics were captured instead via Form 8-K Item 2.02 press releases, Form 10-Q/10-K filings, Syndax Form 8-K Exhibit 99.2 investor presentations, and quarterly earnings call transcripts.
- Global Workforce, Executive Compensation & Sustainability (ESG) › Total Global Full-Time Equivalent Employees › Employees by Region — North America (U.S. & Canada) — Excluded due to insufficient recent consecutive periods.
- Global Workforce, Executive Compensation & Sustainability (ESG) › Total Global Full-Time Equivalent Employees › Employees by Region — Europe (Including Switzerland & UK) — Excluded due to insufficient recent consecutive periods.
- Global Workforce, Executive Compensation & Sustainability (ESG) › Total Global Full-Time Equivalent Employees › Employees by Region — Japan — Excluded due to insufficient recent consecutive periods.
- Global Workforce, Executive Compensation & Sustainability (ESG) › Workplace Safety — Total Recordable Incident Rate (TRIR per 100 FTEs) › Workplace Safety — Lost-Time Incident Rate (LTIR per 100 FTEs) — Excluded due to insufficient recent consecutive periods.
Dữ liệu cập nhật 2026-11-15.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Commercial Demand, Constant-Currency Growth & Guidance (Key #1)
Gross-to-Net (GTN) Sales Allowances, Channel Concentration & Supply Chain (Key #2)
Clinical R&D Execution, Collaboration Economics & Non-GAAP Adjustments (Key #3)
- External Clinical CRO & Contract R&D Expense (ASU 2023-07 Segment Disaggregation) ($M)11 kỳ
- Accrued Clinical Trial & CRO Liabilities (Ending Balance) ($M)32 kỳ
- Commercial Selling & Marketing Expense (ASU 2023-07 Segment Disaggregation) ($M)11 kỳ
- Non-GAAP Adjusted Diluted Net Income (Loss) Per Share ($)17 kỳ
Capital Allocation, Manufacturing Facilities, Equity Awards, Pension & Tax
- Cash Capital Expenditures (Bridged Productive Asset Additions) ($M)35 kỳ
- Property, Plant & Equipment, Gross (Total) ($M)35 kỳ
- Total Operating & Finance Lease Liabilities ($M)7 kỳ
- Marketable Debt Securities — Total Fair Value ($M)18 kỳ
- Total Share-Based Compensation Expense ($M)35 kỳ
- Swiss Defined Benefit Pension Plan — Projected Benefit Obligation (PBO) ($M)8 kỳ
- Cash Income Taxes Paid, Net of Refunds ($M)35 kỳ
Global Workforce, Executive Compensation & Sustainability (ESG)
Incyte Biosciences UK Ltd (#08247692 — Standalone UK Subsidiary Statutory Filings)
Partner Commercialization & Pharmaceutical Industry Benchmarks (External)
Consolidated GAAP Financial Statements Context
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Incyte
- Incyte Form 10-Q (incy-20260930.htm, filed 2026-10-29) ↗
- Incyte Form 10-K (incy-20251231.htm, filed 2026-02-10) ↗
- Incyte Form 8-K Earnings Release (FY2026Q3, filed 2026-11-13) ↗
- UK Companies House — Incyte Biosciences UK Ltd (#08247692) Audited Statutory Accounts FY2025 ↗
- Incyte Form 8-K Earnings Release (FY2025Q4, filed 2026-03-06) ↗
- Incyte Form 10-K (FY2025Q4, filed 2026-02-10) ↗
- Incyte 2025 Global Responsibility Report ↗
- Incyte Form 10-Q (filed 2026-10-29) ↗
- Incyte Form 10-K (filed 2026-02-10) ↗
- Incyte Form 10-Q (FY2026Q3, filed 2026-10-29) ↗
- Incyte Proxy Statement DEF 14A (2026, filed 2026-04-28) ↗
- Novartis Form 6-K (0001114448-26-000014) ↗
See a number that looks wrong?